

Updates for Cigna-Participating Providers

COVID-19 UPDATE

November 2022

COVID-19 Public Health Emergency Period Extended Through January 11, 2023

Since the COVID-19 pandemic began, we have taken important steps to deliver timely accommodations to providers and customers, helping to ensure that customers have continued access to COVID-19 diagnostic services, testing, and treatment in safe settings.

Extension of public health emergency period

To align with the recent [extension](#) of the federal public health emergency (PHE) period, we are again extending the cost-share waiver for diagnostic COVID-19 testing and testing-related services through January 11, 2023 for individuals with Cigna commercial and Cigna Medicare Advantage benefit plans.

New COVID-19 vaccine codes available

As a reminder, Cigna commercial and Cigna Medicare Advantage cover the administration of all FDA or EUA-approved COVID-19 vaccines consistent with [CMS guidelines](#).

- > Two vaccine administration codes, 0124A and 0134A, can now be billed by providers for the new bivalent COVID-19 vaccine booster for adults, effective for dates of service on and after August 31, 2022.
- > Two pediatric vaccine administration codes, 0144A and 0154A, were recently released for the bivalent COVID-19 vaccine booster for children. These codes will soon be billable for dates of service on and after October 12, 2022.

Similar to other emergency use authorized vaccines, Cigna commercial and Cigna Medicare Advantage will reimburse the administration of these vaccines at \$40 per dose, and no prior authorization is required.

For additional information about our coverage of the COVID-19 vaccines, please review our [COVID-19 Vaccine coverage policy](#).

Reimbursement update for COVID-19 antibody treatment bebtelovimab

Throughout the pandemic, the emergency use authorized monoclonal antibody drug bebtelovimab was purchased by the federal government and offered to providers for free. As a result, we did not reimburse for the drug itself when billed with Q0222.

However, on August 15, drug manufacturer Eli Lilly started commercial distribution of their COVID-19 monoclonal antibody therapy, [bebtelovimab \(175 mg\)](#), and the federal government will no

Urgency Meter

3

1. Requires immediate attention
2. Requires attention within seven days
3. No action necessary

longer purchase it. Therefore, effective with August 15 dates of service, Cigna commercial and Cigna Medicare Advantage will reimburse providers consistent with the Centers for Medicare & Medicaid Services rates for doses of bebtelovimab that they purchase directly from the manufacturer. Reimbursement for the administration of the injection will remain the same.

Reimbursement rates are as follows:

- Q0222 (175mg for the drug): \$2,394
- M0222 (administration in facility setting): \$350.50
- M0223 (administration in home setting): \$550.50

As a reminder, no prior authorization is required for the procurement or administration of COVID-19 infusion treatments, including bebtelovimab.

Get all the most up-to-date information

We updated our dedicated [COVID-19 provider web page](#) on October 19, 2022 to highlight the extension of the PHE, provide additional coverage information on available vaccines, and more. You can also access additional Cigna Medicare Advantage billing guidelines from this page.

I encourage you to visit the site to get the latest information.

Thank you again for the quality care you provide and for all that you're doing to help our customers.

If you have questions about how Cigna is responding to COVID-19, please contact me directly anytime.

Thanks again,

Cassandra Reynolds

Provider Relations Executive | Provider Relations & Solution Management

T: 314.412.7750 | F: 1.866.249.7401